> This will enable it to be supplied at a non-exploitative price to Africa and Asia.

It's millions of times easier to copy than to discover. Discovery needs paying for, and the places that don't discover aren't owed things by places that do.

They produce drugs whose patents have expired; drugs still under patent are something they mostly avoid. The term for 3rd party versions of these drugs are often referred to as `generics`, which sees the same drug, but a different name(names also have copyrights that seem to extend longer).

However, if they can tweak the drug and make it something that escapes the patent and still works then good for them and everyone else. Though mindful large pharma is rather tight and lawyer-heavy when it comes to protecting their IP.

As of now it is under patent that expires in 2032, and also not FDA approved, so with how long that process takes, either way, wont see it available anytime soon in drug regulated countries. But grey imports/black market trade in pharma drugs is not to be overlooked.